Modulating immunosuppression in liver transplant patients with COVID-19.

Abstract

We read with great interest the COVID-LT study by C Becchetti et al.Which included 57 liver transplant (LT) patients from 12 European institutions who were diagnosed with coronavirus disease 2019 (COVID-19). Simultaneously, the Spanish Society of Liver Transplantation (SETH) has conducted a nationwide prospective study including 22 transplant institutions and 111 LT patients with COVID-19. Since there were only nine overlapped cases, both cohorts add up to 159 LT patients and taken together their close analysis (table 1) may derive in practical conclusions.